CAS: 126747-14-6; 4-Cyanophenylboronic Acid

相似化合物

171364-82-2 850623-36-8 123088-59-5

上下游产品

4-bromobenzenecarbonitrile di-isopropyl 4-cyanophenylboronate Triisopropyl borate 4-Chlorophenylboronic acid methyl 4-(4-cyanobenzyl)benzoate 4-cyano-1,1'-biphenyl 4-amino-4'-cyanobiphenyl Benzyl 4-[(4-cyanophenyl)methyl]benzoate

4-溴苯腈置于正丁基锂,硼酸三甲酯体系中,用 四氢呋喃 用作溶剂,化学反应生成4-氰基苯硼酸
参考文献:Wavelength Conversion Lanthanide(III)-Cored Complex For Highly Efficient Dye-Sensitized Solar Cells
标题:Wavelength Conversion Lanthanide(III)-Cored Complex For Highly Efficient Dye-Sensitized Solar Cells
摘要:由于短波长的光在紫外区的吸收有限,这些 Dssc 无法有效地用于发电,因此首次成功设计和合成了作为波长转换材料的镧系(III)有芯配合物,用于高效染料敏化太阳能电池.由于黑色染料(bd)在较短波长处的光吸收相对较弱,因此被选为敏化剂.Bd/wcm 器件的整体转换效率显著提高,即使添加的 Wcm 相对较少.与 Dca 一样,Wcm 对 $v_{oc}$ 的增强可能与抑制注入电子和 $i_3{^-}$ 离子之间的电子重组有关.此外,Wcm 还显著提高了短路电流密度,具有很强的紫外光收集效应.从 Eu(III)-Cored 复合物到 $tio_2$ 薄膜的能量转移是通过染料实现的,因此注入 $tio_2$ 表面的电子数量增加,即短路电流密度增加.因此,Bd/wcm 敏化太阳能电池表现出卓越的器件性能,在 Am 1.5 阳光下的转换效率提高了 1.22 倍:基于 Bd/wcm 的 Dssc 的光电性能值非常高,$j_{sc}$为 17.72 Ma/$cm^2$,$v_{oc}$为 720 Mv,转换效率为 9.相比之下,标准 Dssc 的 $j_{sc}$ 为 15.53 Ma/$cm^2$,$v_{oc}$ 为 689 Mv,100 Mw $cm^{-2}$ 时的转换效率为 7.58%.因此,Eu(III)掺杂复合物有望成为高效染料敏化太阳能电池的新型波长转换共吸附剂,通过能量转移过程改善紫外光收集.摘要应为概述文章内容的一个单独段落.
Doi:10.5012/bkcs.2011.32.8.2743

专利信息

专利号:US-2025129021-A1
优先权日:2023-09-19
标 题:Small molecule protein synthesis modulators
发明人：GYGI DAVID; BAHMANYAR SOGOLE SAMI; HAMANN LAWRENCE
权利人:INTERDICT BIO INC
摘要:The present disclosure provides compounds of the formulae herein (e.g., Formula (I), Formula (V)), and pharmaceutically acceptable salts thereof, which are useful for modulating protein synthesis (e.g., modulating synthesis of BCL-2, MYC, CCND1, MCL-1, ALK, KRAS-G12D). The present disclosure also provides pharmaceutical compositions and kits comprising the compounds, or pharmaceutically acceptable salts thereof, and methods of treating or preventing diseases or disorders (e.g., diseases or disorders associated with BCL-2, MYC, CCND1, MCL-1, ALK, KRAS-G12D) by administering to a subject in need thereof the compounds, or pharmaceutically acceptable salts thereof, or pharmaceutical compositions thereof.

专利号:US-6121448-A
优先权日:1995-03-28
标题 :Pyrimidine compounds
发明人：LEWIS ROBERT ANDREWS; GOODBY JOHN WILLIAM; TOYNE KENNETH JOHNSON; HIRD MICHAEL
权利人:SECR DEFENCE BRIT
摘要:The synthesis of novel compound (I) is described: 5-bromo-2-iodopyrimidine may be used for the synthesis of a range of chemical compounds both known and novel. The synthesis of a number of novel liquid crystalline compounds is described.

专利号:US-10226449-B2
优先权日:2013-12-20
标 题:Heterocyclic modulators of lipid synthesis and combinations thereof
发明人：HEUER TIMOTHY SEAN; OSLOB JOHAN D; MCDOWELL ROBERT S; JOHNSON RUSSELL; YANG HANBIAO; EVANCHIK MARC; ZAHARIA CRISTIANA A; CAI HAIYING; HU LILY W; DUKE GREGORY; OHOL-GUPTA YAMINI; O'FARRELL MARIE
权利人:3 V BIOSCIENCES INC
摘要:Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by dysregulation of a fatty acid synthase pathway by the administration of such compounds and combinations of such compounds and other therapeutic agents.

专利号:US-9428502-B2
优先权日:2012-07-03
标题:Heterocyclic modulators of lipid synthesis
发明人：OSLOB JOHAN D; MCDOWELL ROBERT S; JOHNSON RUSSELL; YANG HANBIAO; EVANCHIK MARC; ZAHARIA CRISTIANA A; CAI HAIYING; HU LILY W; WAGMAN ALLAN S
权利人:3-V BIOSCIENCES INC
摘要:Heterocyclic modulators of lipid synthesis are provided as well as pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds; and methods of treating conditions characterized by disregulation of a fatty acid synthase pathway by the administration of such compounds.

专利号:US-2012077802-A1
优先权日:2009-06-10
标题 :Histamine h3 inverse agonists and antagonists and methods of use thereof
发明人：CHYTIL MILAN; ENGEL SHARON R; FANG QUN KEVIN
权利人:CHYTIL MILAN; ENGEL SHARON R; FANG QUN KEVIN; SUNOVION PHARMACEUTICALS INC
摘要:Provided herein are spiro-cyclic compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, including, e.g., neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release of various neurotransmitters, such as, e.g., histamine, acetylcholine, norepinephrine, and dopamine (e.g. at the synapse). Pharmaceutical compositions containing the compounds and their methods of use are also provided herein.

专利号:US-2012172350-A1
优先权日:2009-09-11
标题 :Histamine h3 inverse agonists and antagonists and methods of use thereof
发明人：CHYTIL MILAN; ENGEL SHARON R; FANG QUN KEVIN
权利人:CHYTIL MILAN; ENGEL SHARON R; FANG QUN KEVIN; SUNOVION PHARMACEUTICALS INC
摘要:Provided herein are fused imidazolyl compounds, methods of synthesis, and methods of use thereof. The compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, including, e.g., neurological disorders and metabolic disorders. Compounds provided herein inhibit the activity of histamine H3 receptors and modulate the release of various neurotransmitters, such as, e.g., histamine, acetylcholine, norepinephrine, and dopamine (e.g. at the synapse). Pharmaceutical compositions containing the compounds and their methods of use are also provided herein.